Business Wire·Aug 12, 2026, 4:05 PM ET

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

ATRA

Atara Biotherapeutics reported a productive Type A meeting with the FDA confirming the opportunity to resubmit the tabelecleucel Biologics License Application (BLA) based on the Phase 3 ALLELE trial.
Partner Pierre Fabre Pharmaceuticals intends to submit an updated dataset with additional patients and longer follow-up from the ALLELE study.
The company achieved a 87% year-over-year reduction in total costs and operating expenses for the second quarter of 2026.
Atara held $9.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026, with a cash runway expected to fund operations into mid-2027.
Total revenues for the second quarter 2026 were $0.6 million, down from $17.6 million in the same period of 2025 due to the accelerated recognition of deferred revenue in the prior year.
Net cash used in operating activities was $3.3 million for the second quarter 2026, compared to $7.4 million in the second quarter of 2025.
Research and development expenses decreased to $1.3 million in the second quarter 2026 from $7.3 million in the same period of 2025.
General and administrative expenses decreased to $3.8 million in the second quarter 2026 from $6.5 million in the same period of 2025.
The company reported a net loss of $4.8 million, or ($0.32) per share, for the second quarter 2026, compared to a net income of $2.4 million, or $0.20 per share, in the same period of 2025.
Atara is eligible for a $31 million milestone payment upon FDA approval of the tabelecleucel BLA, along with double-digit tiered royalties on net sales.